effect overlay
activetrials
Dementia
Dementia
Anavex 003

A Phase IIa Study of ANAVEX2-73 Adaptive Trial Design with repeated doses, Maximum Tolerated Dose Finding, Pharmacodynamic Investigation and Bioavailability Evaluation in Patients with Mild to Moderate Alzheimer’s Disease With a 52 week Open Label Follow-Up period 
 

HREC: 2016.097
Principal Investigator: Dr Christopher Kyndt
Coordinator contact: Lauren Martell
Funding: Commercial
Dementia
Dementia
COG-Stroke

Acute Brain Imaging and Cognitive Determinants of Post-Stroke Cognitive Outcomes

HREC: 2023.027
Principal Investigator: Dr Ashley Park
Coordinator contact:
Funding: Non-Commercial
Dementia
Dementia
AusCADASIL

An Australian Cohort of CADASIL

HREC: 2023.213
Principal Investigator: Prof Amy Brodtmann
Coordinator contact: Dr Ashley Park
Funding: Non-Commercial
Dementia
Dementia
3D

Deferiprone to Delay Dementia (The 3D Study): a clinical proof of cencept study
 

HREC: 2017.172
Principal Investigator: Dr Christopher Kyndt
Coordinator contact: Lauren Martell
Funding: Commercial
Dementia
Dementia
XanaMIA

A Phase 2b, Double-Blind, Placebo-Controlled, Parallel-Groups, 36-Week, 2-Arm Trial to Assess the Safety, Tolerability, and Efficacy of Xanamem® 10 mg daily in Patients with Mild or Moderate Dementia due to Alzheimer's Disease

HREC: 2024.032
Principal Investigator: A/Prof David Darby
Coordinator contact: Lesley-Anne Attard
Funding: Commercial